Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years
The GlaxoSmithKline Vaccine HPV-007 Study Group
The Lancet (British edition), 2009, Vol.374 (9706), p.1975-1985 [Periódico revisado por pares]Elsevier Ltd
Texto completo disponível